Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A

Evaluation of immune responses to adeno-associated virus (AAV)-mediated gene therapies prior to and following dose administration plays a key role in determining therapeutic safety and efficacy. This report describes up to 3 years of immunogenicity data following administration of valoctocogene roxa...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Brian R., Veron, Philippe, Kuranda, Klaudia, Hardet, Romain, Mitchell, Nina, Hayes, Gregory M., Wong, Wing Yen, Lau, Kelly, Li, Mingjin, Hock, M. Benjamin, Zoog, Stephen J., Vettermann, Christian, Mingozzi, Federico, Schweighardt, Becky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854299/
https://www.ncbi.nlm.nih.gov/pubmed/33309883
http://dx.doi.org/10.1016/j.ymthe.2020.12.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854299/
https://www.ncbi.nlm.nih.gov/pubmed/33309883
http://dx.doi.org/10.1016/j.ymthe.2020.12.008

Ejemplares similares